Brokerages forecast that Spring Bank Pharma (NASDAQ:SBPH) will report earnings of ($0.47) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Spring Bank Pharma’s earnings. Spring Bank Pharma reported earnings of ($0.54) per share in the same quarter last year, which indicates a positive year over year growth rate of 13%. The firm is scheduled to announce its next quarterly earnings results on Monday, July 30th.
On average, analysts expect that Spring Bank Pharma will report full-year earnings of ($1.82) per share for the current fiscal year, with EPS estimates ranging from ($1.87) to ($1.78). For the next year, analysts forecast that the business will report earnings of ($2.42) per share, with EPS estimates ranging from ($2.94) to ($2.03). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Spring Bank Pharma.
Spring Bank Pharma (NASDAQ:SBPH) last announced its quarterly earnings data on Friday, April 27th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.15.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BVF Inc. IL grew its position in Spring Bank Pharma by 26.2% in the fourth quarter. BVF Inc. IL now owns 823,474 shares of the company’s stock valued at $11,076,000 after acquiring an additional 170,798 shares in the last quarter. Millennium Management LLC acquired a new stake in Spring Bank Pharma in the fourth quarter valued at approximately $676,000. Candriam Luxembourg S.C.A. acquired a new stake in Spring Bank Pharma in the fourth quarter valued at approximately $269,000. Morse Asset Management Inc grew its position in Spring Bank Pharma by 12.9% in the first quarter. Morse Asset Management Inc now owns 165,775 shares of the company’s stock valued at $2,492,000 after acquiring an additional 18,900 shares in the last quarter. Finally, AXA grew its position in Spring Bank Pharma by 7.6% in the fourth quarter. AXA now owns 266,585 shares of the company’s stock valued at $3,583,000 after acquiring an additional 18,859 shares in the last quarter. 29.17% of the stock is owned by hedge funds and other institutional investors.
SBPH opened at $13.96 on Monday. The company has a market cap of $181.73 million, a P/E ratio of -7.47 and a beta of -0.37. Spring Bank Pharma has a 1 year low of $10.81 and a 1 year high of $18.93.
Spring Bank Pharma Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharma and related companies with MarketBeat.com's FREE daily email newsletter.